Primary Dysmenorrhea
Conditions
Brief summary
This study will be conducted to study the effect of virtual reality therapy on prostaglandin levels in adolescent females with primary dysmenorrhea.
Detailed description
Primary dysmenorrhea is thought to be caused by excessive levels of prostaglandins, which are hormones that stimulate the uterus to contract during menstruation and childbirth, Treatment must be tailored to individual patient symptoms. Pharmacologic management with non-steroidal anti-inflammatory medications and/or combined hormonal contraceptives is most common. Heat therapy, exercise, vitamins and dietary supplements have limited evidence and can be offered for patients seeking non-pharmacologic adjunctive or alternative options. Greater awareness for both health-care providers and patients allow for early intervention to reduce impact on quality of life and life course potential. The significance of this study to assess the effect of virtual reality therapy on primary dysmenorrhea.
Interventions
All participants in the two groups will receive pharmacological treatment in the form of ibuprofen 400 mg, three times per day, during the first 2 days of menstruation, for 3 menstrual cycles.
OTHERVirtual reality
The experimental group will receive virtual reality during the first 2 days of menstruation, for 3 menstrual cycles.
Sponsors
Benha National University
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)
Eligibility
Sex/Gender
FEMALE
Age
17 Years to 21 Years
Healthy volunteers
No
Inclusion criteria
* Age 17- 21 years old. * The body mass index (BMI) \< 30 kg/m2. * Unmarried females. * Females with dysmenorrhea pain. * Females with regular menstrual cycles. * Females with normal gynecology.
Exclusion criteria
* Have a pathological disease related to reproduction. * Students who use analgesic drugs for 3 months/3 menstrual cycles. * Students with menstrual pain secondary to diagnosed organic or inflammatory causes.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Visual Analogue Scale (VAS) | 12 weeks | Participants in both groups will complete the visual analogue scale (VAS) before the start of treatment and after 3 menstrual cycles of treatment. The VAS is a 10 cm horizontal line on which the participants' pain intensity is represented by a point between the extremes of no pain at all and worst pain imaginable. Each girl will be asked to mark a point on the line between the extreme that was related to her pain intensity. Then, the distance will be measured each time from the left end of the line to the marked point to obtain the VAS score for pain intensity of dysmenorrhea. |
| Assessment of Prostaglandin Levels | 12 weeks | Blood samples will be collected from each girl in both groups to measure the levels of plasma PGF2α before the start of treatment and after 3 menstrual cycles of treatment. |
Countries
Egypt
Contacts
Primary ContactSally Mohamed Saeed, PhD
Outcome results
None listed